At this time, Fycompa (perampanel) is available in brand-name form only. After the first patent for the drug expires in June 2021, however, companies may be allowed to manufacture a generic Fycompa product. Although perampanel is considered the "generic name" for Fycompa, it is simply the active ingredient in the drug and not a generic version of it.
Fycompa™ (perampanel) is a prescription anti-seizure medication. It is approved to treat partial seizures in people with epilepsy.
Fycompa is made by Eisai, Inc. It is currently protected by a patent and exclusivity rights that prevent generic Fycompa from being manufactured in the United States.
The first patent for Fycompa is set to expire in June 2021. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Fycompa uses. Once the patent and exclusivity rights expire, there may be several companies that manufacture a generic Fycompa drug.
No -- perampanel is the active ingredient in Fycompa, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.